Register for SOSV HAX Investor Showcase – April 1, 2026

heXembio

Rejuvenating Human Blood Cells for Improved Healthspan

Company details

HexemBio is pioneering the world’s first blood stem cell rejuvenation therapy, a breakthrough platform emerging from >15 Millions from NIH. The company has raised $7.5 million in Seed funding and recently held a successful FDA Pre-IND meeting in January 2026 after being granted Orphan Drug Designation. Its technology, published in Nature, has been featured in The New York Times. The founding team includes 2 MDs, 2 PhDs, and 1 MBA from MIT, Harvard, UC Berkeley, Mayo Clinic, and Boehringer Ingelheim – second-time founders, Y Combinator alumni, and recipients of DARPA, NIH, and U.S. Presidential awards. HexemBio is backed by Draper VC, SOSV, Seraphim VC, Venture Science, Zentynel, Zaka VC, Innovation Works, Gaingels, Treeo VC, NY Venture. Its advisory includes Robert Langer (Moderna co-founder), Peter Barton Hutt (Moderna board), Joanne Kurtzberg, MD (leading U.S. clinician), David Harris, PhD (founder, first U.S. blood bank), Jens Nielsen, PhD (CEO, BII – $3B Novo Nordisk), and Felipe Sierra, PhD (former Director, Division of Aging, NIA/NIH).

In the United States, people over the age of 55 account for over 55% of healthcare spending—about $2.5 trillion annually.

heXembio Quote Image
Gabriel Levesque-Tremblay, co-founder and CEO
This is a trillion-dollar market because we're talking about the rejuvenation of almost any adult and the potential to treat or prevent 20 diseases. We are proud to push the boundaries of possibilities in the human longevity space.

Team

Mo Ebrahimkhani

CSO

Get In Touch with heXembio

Please tell us a little bit about yourself and why you'd like to get connected. heXembio + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.